OPSONIC HAS BEEN FINANCED THROUGH A CONVERTIBLE LOAN

During 2009 ChronTech out licensed an exclusive right to the RAS® technology to
the American company, Opsonic Therapeutics, and in return received 20% of
outstanding Opsonic stock.

Opsonic Therapeutics has received a convertible loan for USD 750,000 from an
American private investor, with a possibility to increase the loan up to two
million USD on the same terms. The loan will bear interest at the rate of 5 %
and with a three year maturity.

The loan will be converted into shares on the same terms as those on the next
larger financing of Opsonic.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.